Vox Sanguinis最新文献

{"title":"Response to 'Beyond universal mitigation: Risk-stratified approaches for preventing vasovagal reactions in blood donors'.","authors":"Radheshyam Meher, Gopal Patidar","doi":"10.1111/vox.70342","DOIUrl":"https://doi.org/10.1111/vox.70342","url":null,"abstract":"","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148664510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo recovery and in vitro quality assessment of apheresis red blood cells stored for 42 days in non-DEHP disposable sets.","authors":"Bethany L Brown, Samatha E Mack, Emily Mason, Michael Wellington, Neeta Rugg, Susanne Marschner, Christina Gloor, Rebecca L Sedjo, Nero Evero, Joseph Rice, Jeremiah Gorman, Jack P Rhodes, Richard Cook, Caroline Alquist","doi":"10.1111/vox.70289","DOIUrl":"10.1111/vox.70289","url":null,"abstract":"<p><strong>Background and objectives: </strong>Di(2-ethylhexyl) phthalate (DEHP) has been used in blood bag manufacturing for decades, but concern about its potential toxicity has prompted regulatory efforts to eliminate it from medical devices, including blood bags. As manufacturers transition to non-DEHP materials, evaluation is required to ensure blood component quality in modified bag systems. Investigational Trima Accel disposables were developed using plasticizers approved as DEHP alternatives per the European Pharmacopoeia. Red blood cells (RBCs) were collected, and two consecutive studies evaluated in vitro quality and in vivo RBC recovery.</p><p><strong>Study design and methods: </strong>Leukoreduced RBCs (LR-RBCs) were stored in Additive Solution 3 (AS-3) at 2-6°C for 42 days. In vitro quality parameters measured on days 0, 35 and/or 42 were assessed against US Food and Drug Administration (FDA) and European Directorate for the Quality of Medicines & HealthCare (EDQM) acceptance criteria. A radiolabelling study evaluated in vivo 24-h RBC recovery using the FDA criteria.</p><p><strong>Results: </strong>Key FDA criteria were met, including haemolysis, which remained below the acceptable limit throughout 42 days of storage. All EDQM criteria were met except Day 0 haematocrit, with 8 units outside the specified range and the confidence interval (CI) lower bound at 77.6%. All FDA criteria for in vivo 24-h RBC recovery were met.</p><p><strong>Conclusion: </strong>Apheresis LR-RBCs collected with Trima Accel systems using non-DEHP disposables and stored for 42 days met key FDA and EDQM criteria, with any in vitro parameter failures considered artefactual. Products also met FDA's 24-h in vivo RBC recovery criteria, supporting their use as acceptable transfusable products.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1173-1180"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An automatic consult reply system for therapeutic plasma exchange using retrieval-augmented generation.","authors":"Jong Kwon Lee, Sooin Choi, Sholhui Park, Qute Choi, Sang-Hyun Hwang, Duck Cho","doi":"10.1111/vox.70280","DOIUrl":"10.1111/vox.70280","url":null,"abstract":"<p><strong>Background and objectives: </strong>Large language models (LLMs) show promise for clinical decision support but remain vulnerable to factual errors. Retrieval-augmented generation (RAG) mitigates this limitation by grounding outputs in authoritative domain knowledge. Therapeutic plasma exchange (TPE) requires consistent, guideline-driven decisions based on the 2023 American Society for Apheresis (ASFA) recommendations. This study aimed to evaluate whether an RAG-based framework could improve accuracy, reliability and standardization of decision support for TPE, compared to conventional LLMs.</p><p><strong>Materials and methods: </strong>We built a hybrid RAG pipeline combining BAAI/bge-base-en-v1.5 embeddings with Chroma and BM25, coupled with structured prompts that encode ASFA categories and grades, Health Insurance Review and Assessment (HIRA) service criteria, and plasma volume computation rules. Thirty de-identified real-world consultation cases were converted into standardized queries. Across six RAG and three non-RAG generative pre-trained transformer (GPT)-series model configurations, each case was answered five times (1,350 outputs). Performance was assessed by item-level accuracy for six elements (diagnosis, ASFA category, grade, insurance applicability, plasma volume, and replacement fluid) and reproducibility on 14 disease-name prompts. Response time and output length were also analyzed.</p><p><strong>Results: </strong>RAG configurations consistently outperformed non-RAG baselines across items, with the largest gains in plasma-volume calculation and ASFA classification. Reproducibility was markedly higher with RAG across repeated runs. Among all configurations, RAG GPT-4.1-mini showed the most balanced and superior performance, delivering high accuracy with low latency.</p><p><strong>Conclusion: </strong>A guideline-grounded RAG approach substantially enhances the accuracy, stability and standardization of TPE consultation compared with conventional LLMs. This RAG-TPE framework demonstrates the feasibility of reliable, clinically oriented decision support in transfusion medicine, warranting further evaluation in prospective clinical workflows.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1192-1200"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147842447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of breakpoint regions and single nucleotide variations of RHD hybrid alleles by long-read sequencing.","authors":"Ti-Cheng Chang, Jing Yu, Bensheng Ju, Teha Kim, Melanie Loyd, Granger Ridout, Geoffrey Neale, Jane S Hankins, Mitchell J Weiss, Gorka Ochoa, Sunitha Vege, Stella T Chou, John Easton, Yan Zheng","doi":"10.1111/vox.70292","DOIUrl":"10.1111/vox.70292","url":null,"abstract":"<p><strong>Background and objectives: </strong>RHD*03N.01 (RHD*DIIIa-CEVS(4-7)-D) and RHD*01N.06(RHD*D-CEVS(4-7)-D) are hybrid alleles that encode a partial C antigen, resulting in increased risk of C alloimmunization in individuals without a conventional C antigen. As detection of the hybrid alleles remains challenging, new markers can aid accurate identification, ensuring provision of C-negative blood to individuals at risk.</p><p><strong>Materials and methods: </strong>To identify breakpoint regions and distinct intronic single nucleotide variations (SNVs) of the hybrid alleles, Pacific Bioscience (PacBio) long-read sequencing was performed in two patients with RHD*DIIIa-CEVS(4-7)-D and one patient with RHD*D-CEVS(4-7)-D; two patients without hybrid alleles served as controls. Association of the identified SNVs with RHD*DIIIa-CEVS(4-7)-D was subsequently evaluated in 910 patients with sickle cell disease.</p><p><strong>Results: </strong>The 5' breakpoint region of RHD*DIIIa-CEVS(4-7)-D was found in intron 3 at chr1:25293827-25293837 (RHD c.486+3036-3046) and chr1:25293907-25293980 (RHD c. 486+3116-3189) for the two patients. The 5' breakpoint region of RHD*D-CEVS(4-7)-D was at chr1:25294633-25295072 (RHD c.486+3842-4281). Both hybrid alleles had identical 3' breakpoint region in intron 7 at chr1:25310252-25310377 (RHD c.1073+3523-3648). Three intronic SNVs were found in RHD*DIIIa-CEVS(4-7)-D: chr1:25293603 (RHD c.486+2812) G>A, chr1:25293891 (RHD c.486+3100) A>G in intron 3; chr1:25310934 (RHD c.1073+4205) T>C in intron 7. In 910 patients, the SNVs demonstrated high sensitivities (94.83%, 94.83%, 96.55%) and specificities (99.88%, 99.88%, 99.88%) in detecting RHD*DIIIa-CEVS(4-7)-D. One SNV, chr1:25294894 (RHD c.486+4103) T>C in intron 3, was identified in RHD*D-CEVS(4-7)-D, but not confirmed due to lack of additional carriers.</p><p><strong>Conclusion: </strong>Three intronic SNVs can be used to accurately identify RHD*DIIIa-CEVS(4-7)-D.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1235-1244"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron recovery dynamics after whole blood donation and the effect of low-dose iron supplementation in Japanese donors.","authors":"Katsuya Ikuta, Gaku Kondo, Kiichi Aoki, Noriko Namba, Rie Okubo, Nelson H Tsuno, Fumihiko Ishimaru, Yoshie Yamauchi, Shinichi Kishimoto, Yukiko Watanabe, Chiharu Origuchi, Shuichi Kino","doi":"10.1111/vox.70291","DOIUrl":"10.1111/vox.70291","url":null,"abstract":"<p><strong>Background and objectives: </strong>Iron deficiency (ID) poses a non-negligible risk for blood donors, yet longitudinal data on iron status and whether low-dose iron-containing supplements improve ID among Japanese donors are scarce. This study aimed to elucidate these issues.</p><p><strong>Materials and methods: </strong>Sixty-six healthy Japanese donated 400 mL of whole blood (WB) and underwent scheduled blood samplings. Fourteen participants discontinued follow-up; 52 donors completed the second 400 mL WB donation at Week 48. Participants were subsequently provided supplements containing 6 mg/day of ferric citrate for 12 weeks, with continued monitoring through Week 48; the total duration of participation in the study was 96 weeks. Haematological data were analysed using a linear mixed-effects model.</p><p><strong>Results: </strong>In men, serum ferritin (sFer) declined from 116.2 ng/mL (95% confidence interval [95% CI]: 88.0-144) to 83.7 ng/mL (55.5-112) at Week 4 and returned to baseline by Week 36. In women, sFer decreased from 29.2 ng/mL (21.74-36.7) to 16.6 ng/mL (9.16-24.1) at Week 4 and returned to baseline at Week 24. Recovery of sFer was slower than that of haemoglobin (Hb) in both sexes. Iron supplementation did not affect the recovery of Hb and sFer in men and Hb in women, whereas women showed a significant increase in sFer at Week 16.</p><p><strong>Conclusion: </strong>Although Hb recovered quickly after 400 mL WB donation, replenishment of iron stores took longer. Low-dose iron supplementation facilitated the recovery of iron stores in women. These findings highlight the need for monitoring iron status and may inform strategies to support donor safety and maintain adequate blood supply.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1147-1156"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147943060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of serological reactivity in genetically confirmed Rh variants within a recipient population.","authors":"Maïlis Lauwers, Philippe Akiki, Samy Bensaid, Saad Bakrim, Mélanie Monfort, Hanane El Kenz","doi":"10.1111/vox.70285","DOIUrl":"10.1111/vox.70285","url":null,"abstract":"<p><strong>Background and objectives: </strong>Detecting Rh variants in transfusion recipients is essential to prevent alloimmunization. This study compared the serological reactivity of various monoclonal antibodies using two techniques (gel column agglutination and microplate technology at room temperature) in relation to genetically confirmed Rh variants.</p><p><strong>Materials and methods: </strong>Over an 18-month period, all EDTA blood samples referred to the molecular laboratory were analysed. RHD and RHCE genotyping was performed, and samples carrying at least one variant allele underwent serological testing. Statistical analysis was performed using the McNemar test (p < 0.05).</p><p><strong>Results: </strong>Among 610 samples, 118 (19%) carried at least one Rh variant. The most frequent alleles were RHCE*CeRN (n = 39) and RHD*weak D type 1 (n = 14). Weak RhD (types 1 and 3) and partial RhD from RHD*DAR were serologically weakened (<4+) with both methods. Homozygosity for RHCE*CeRN was suggested by serological weakening of RH5 with both methods, whereas heterozygosity was indicated by serological weakening of RH2 with microplate only. Other variants with a few samples (RH1 of RHD*weak D type 2 and 5, RH2 of RHD*RHD-CE (4-7)-D, RH3 of RHCE*cEIV, RH4 of RHCE*ceJAL and RH5 of RHCE*ceMO.01 and RHCE*ceAR) showed weak serological intensities but lacked statistical confirmation. Finally, 39% of Rh variants were not detected as serologically weakened by both serological methods.</p><p><strong>Conclusion: </strong>Phenotyping remains the first-line screening tool. Weak serological intensities help guide molecular investigations. However, detection of Rh variants using serology alone is highly variable. Combining different clones and techniques improves sensitivity.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1220-1227"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel FUT1 variant, c.[35C>T;133_136dupCGCC], underlies a group A para-Bombay phenotype in a Chinese blood donor.","authors":"Jue Hou, Xue Chen, Xuemei Zhang, Jianying Yang, Ying Li","doi":"10.1111/vox.70288","DOIUrl":"10.1111/vox.70288","url":null,"abstract":"<p><strong>Background and objectives: </strong>The para-Bombay phenotype is characterized by H antigen deficiency and the natural production of antibody against the I and H antigens (anti-IH), some of which are occasionally clinically significant. It genetically results from the presence of two non-functional FUT1 alleles coupled with at least one functional FUT2 allele. We present the serological and molecular characterization of a para-Bombay phenotype case, which led to the identification of a novel FUT1 allele.</p><p><strong>Materials and methods: </strong>A sample from a blood donor was identified as a result of a discrepancy between forward and reverse typing. This sample subsequently underwent serological typing for A, B and H antigens in accordance with the American Association of Blood Banks Technical Manual. Furthermore, Sanger sequencing and nanopore sequencing were employed to analyse the ABO, FUT1 and FUT2 genes.</p><p><strong>Results: </strong>The donor was found to have an H-deficient phenotype and the presence of anti-IH. Sanger sequencing identified an ABO*A1.01/ABO*O.01.02 genotype. Nanopore sequencing showed a compound heterozygous state in FUT1, represented by the FUT1*01W.09 allele and a novel FUT1 allele carrying the c.[35C>T;133_136dupCGCC] variant. The FUT2 genotype was determined as FUT2*01/FUT2*01W.02.01.</p><p><strong>Conclusion: </strong>This study identifies a novel FUT1 allele characterized by the c.[35C>T;133_136dupCGCC] variant that impairs H antigen expression on red blood cells, thereby contributing to the understanding of FUT1 allele diversity.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1250-1255"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.","authors":"Lixin Wang, Li Wang, Ying Huang, Fu Cheng, Bin Tan","doi":"10.1111/vox.70316","DOIUrl":"10.1111/vox.70316","url":null,"abstract":"<p><strong>Background and objectives: </strong>Haemolytic disease of the foetus and newborn (HDFN) caused by anti-M antibodies is historically considered clinically insignificant. This systematic review aims to comprehensively evaluate the literature on anti-M-mediated HDFN, assessing its clinical spectrum, risk factors, management and outcomes.</p><p><strong>Materials and methods: </strong>A systematic search was conducted across PubMed, Chongqing VIP information Co., Ltd (CQVIP), Wanfang Data and China National Knowledge Infrastructure (CNKI) from database inception (PubMed 1966, CNKI 1979) to 30 April 2024. Studies published in English or Chinese, which reported diagnostic parameters, clinical management or quantifiable outcomes of anti-M-mediated HDFN, were included. Data on maternal history, serological results, interventions and perinatal outcomes were extracted and analysed.</p><p><strong>Results: </strong>Among cases reported in the Chinese and English language literature included in this review, a marked geographical concentration was observed, primarily reflecting the inclusion of Chinese-language databases. Severe HDFN was significantly associated with multiparity, adverse pregnancy history and elevated antibody titres (p < 0.05). Notably, 65% (61/94) of neonates tested were direct antiglobulin test (DAT)-negative, and 50% (14/28) of anti-M samples exhibited stronger reactivity at 4°C/room temperature than at 37°C. Clinically, antenatal interventions were required in 20.3% (25/123) of pregnancies. Outcomes included total pregnancy loss in 11.4% (14/123) and persistent neonatal anaemia in 13.0% (14/108) of live births.</p><p><strong>Conclusion: </strong>Within the Chinese and English language literature, anti-M-mediated HDFN is shown to be a cause of severe perinatal morbidity and mortality, with a pronounced overrepresentation of severe cases in Asian populations. The findings highlight the necessity of dual-temperature serological testing and vigilant monitoring of at-risk pregnancies. The observed ethnic concentration warrants further investigation.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1129-1137"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148370007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Portable radio-frequency identification device for batch identification and rapid verification of blood in emergency medical rescue.","authors":"Shuo Liang, Lei Wang, Dongdong Li, Yuxin Zhang, Weiming Wang, Kun Liu, Fengying Qi, Ruotong Zhang, Xunuo Li, Xiaoyang Yi, Ting Zhang, Yang Yu, Qiuxia Fu, Shaoduo Yan","doi":"10.1111/vox.70287","DOIUrl":"10.1111/vox.70287","url":null,"abstract":"<p><strong>Background and objectives: </strong>Blood is indispensable in emergency medical care and serves as mortality. However, in disaster zones and other challenging environments, batch identification and rapid allocation of blood supplies remain particularly difficult. A portable blood batch identification device (PBBID) based on ultra-high-frequency (UHF) radio-frequency identification (RFID) technology was developed to improve the efficiency of blood verification management in complex environments.</p><p><strong>Materials and methods: </strong>PBBID has a lightweight foldable cabin and an integrated composite protective layer and UHF RFID antenna and is equipped with a dedicated blood management terminal. Its function, identification rate and accuracy were tested, and blood quality was assessed via blood count, biochemical analysis and haemolysis rate assay.</p><p><strong>Results: </strong>Folded PBBID occupies 24.92% of the expanded volume, unfolding takes 23.68 ± 6.00 s and can identifying 40 blood units in 5.37 ± 0.48 s. During the storage period, fixed-frequency scanning did not significantly affect the quality of red blood cells. However, intensive scanning exceeding 300 times led to a notable increase in the haemolysis rate.</p><p><strong>Conclusion: </strong>With its foldable design, rapid batch identification capability and operational simplicity, PBBID markedly enhances the efficiency and accuracy of blood management in emergency medical rescue. Under conventional conditions, it does not compromise blood quality and can shorten the time required for transfusion and emergency treatment of patients with trauma, potentially establishing it as a valuable tool in pre-hospital and emergency medical rescue operations.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1165-1172"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147943083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between NT-proBNP and false-positive Coombs test in patients with heart failure and elevated NT-proBNP.","authors":"Ana Lamilla Álvarez, María Asunción Cámara Rodenas, Sofía Russo Botero, Pau Aracil Boigues, Cristina Játiva Sáez, Elena Vidal Rico, Elena Santos Cañamares, Alma Rangel Algaba, Sebastian Ortiz-Zuluaga, Josefa Esperanza Marco Buades, Lorenzo Fácila Rubio, José Pérez-Silvestre, María de la Encarnación López-Pavía","doi":"10.1111/vox.70284","DOIUrl":"10.1111/vox.70284","url":null,"abstract":"<p><strong>Background and objectives: </strong>The human antiglobulin test or Coombs' test is a key tool in the diagnosis and classification of haemolytic anaemia and could present as falsely positive. A retrospective study has described that B-type natriuretic peptide (NT-proBNP), a biomarker used for heart failure (HF), could be an additional cause of false positives in the Coombs test.</p><p><strong>Materials and methods: </strong>A prospective, observational, single-centre study was conducted in adult patients diagnosed with HF between October 2024 and March 2025 at a tertiary hospital. The Coombs' test was considered as false positive in cases in which the specificity of the test included immunoglobulin G (IgG), the subsequent elution yielded a negative result, and blood haemolysis parameters were within normal ranges.</p><p><strong>Results: </strong>Thirty-six patients were included, of whom nine (25%) had a false-positive Coombs test. These patients had significantly higher levels of NT-proBNP (10,825 pg/mL [2587-35,000] vs. 3314 pg/mL [278-11,856], p = 0.0076) and lower glomerular filtration rate (35.3 mL/min/1.73 m² [23.6-46.3] vs. 63.3 mL/min/1.73 m² [21.9-90.0], p = 0.0055) compared to patients with a negative Coombs test. No statistically significant associations were found with drugs used concomitantly for HF.</p><p><strong>Conclusion: </strong>The results suggest that elevated NT-proBNP could also be a cause of false positives in the Coombs test.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"1245-1249"},"PeriodicalIF":1.6,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}